2015 Revenue: $4.77 billion
HQ: Florham Park, NJ
Zoetis has experienced more than its share of drama ever since it was spun off from Pfizer ($PFE) in 2013. Not long after becoming an independent company, activist investor William Ackman of Pershing Square Capital bought up a large stake of the company, started griping about its high cost structure and pressured executives to sell the animal health outfit. Zoetis CEO Juan Ramón Alaix and his team acted fast to slim down, rolling out a plan to cast off 5,000 underperforming SKUs, exit 10 manufacturing plants and slash 165 jobs. And they kept their eyes on innovation, launching several new products including a hotly demanded drug to treat allergic dermatitis in dogs, Apoquel, and making an entrée into the fast-growing market for fish vaccines by buying Norway-based Pharmaq for $765 million. The initiatives seem to be working: Zoetis’ operational revenues grew 8% in 2015 and its adjusted net income jumped 13% to $889 million.
Zoetis beats estimates in Q4 but dampens 2016 sales forecast on currency woes
Zoetis R&D chief Catherine Knupp on innovation and the fight to stay atop animal health
Zoetis shareholders applaud $765M Pharmaq buy and strong earnings